| Document |
Document Title |
|
WO/2023/141044A1 |
Disclosed herein are formulations of small molecule GIP/GLP-1 dual receptor agonists and uses thereof.
|
|
WO/2023/139626A1 |
Interoception is the mechanism by which an individual is informed about the status of its own body. When interoception becomes dysfunctional, it turns into a deleterious event for the health status of an individual. The use of calcitonin...
|
|
WO/2023/140385A1 |
A pharmaceutical composition for treating or preventing at least one disease selected from the group consisting of inflammatory bowel disease and intestinal tumor, said pharmaceutical composition comprising an inhibitor for the binding o...
|
|
WO/2023/140664A1 |
The present invention relates to: a pharmaceutical composition for preventing or treating liver fibrosis induced by non-alcoholic steatohepatitis, containing, as an active ingredient, an expression inhibitor of lipocalin 2 or a receptor ...
|
|
WO/2023/137671A1 |
L-N-isobutyryl cysteine (L-NIBC) -bound gold cluster Au 15 (L-NIBC) 13, its use for treating multiple sclerosis, Alzheimer's disease (AD), liver cirrhosis, diabetes, Parkinson's disease (PD) or glaucoma, and the use of it for manufacturi...
|
|
WO/2023/138657A1 |
A quinoline amine compound, a preparation method therefor, and the use thereof in medicine. Specifically, the present disclosure relates to a quinoline amine compound represented by general formula (I), a preparation method therefor, a p...
|
|
WO/2023/138644A1 |
Provided is a new polypeptide. The new polypeptide shows a significant effect of relieving intestinal lumen distension in pharmacodynamic tests of a Brachydanio Rerio inflammatory bowel disease model and a rat inflammatory bowel disease ...
|
|
WO/2023/139106A2 |
The present application relates to novel peptides that are derivatives of glucose-dependent insulinotropic peptide (GIP) analogues with improved GIP antagonistic activity, and to the pharmaceutical use of the GIP derivatives. The GIP der...
|
|
WO/2023/138191A1 |
Disclosed in the present invention are an oral care composition, and a preparation method therefor and the use thereof. The oral care composition comprises a drug-loaded micelle, wherein the drug-loaded micelle comprises a polymer micell...
|
|
WO/2023/138147A1 |
The present invention relates to the field of medicinal chemistry. Disclosed are a triptolide prodrug, a preparation method therefor and a pharmaceutical use thereof. The preparation steps are: 1, making triptolide react with acyl chlori...
|
|
WO/2023/137659A1 |
A series of polymers having the properties of acid-sensitive degradation and temperature sensitivity and a drug loading composition thereof. A polymer has a structure represented by formula (1) and has the properties of degradation and t...
|
|
WO/2023/140700A1 |
The present invention provides a composition for treating inflammatory bowel disease or a method for the screening of drugs for treating inflammatory bowel disease, the composition comprising, as an active ingredient, a material for redu...
|
|
WO/2023/140695A1 |
The present invention relates to a composition for improving intestinal health and function comprising: a milk-derived exosomes; and a therapeutic agent, wherein the therapeutic agent is DNA, RNA, or a small molecule, and the therapeutic...
|
|
WO/2023/138593A1 |
Provided in the present invention are an antibacterial stent having a micro-nano double-layer structure, and a preparation method therefor and the use thereof, which belong to the technical field of oral medical products. The method for ...
|
|
WO/2023/140603A1 |
The present invention relates to a composition for the prevention, amelioration or treatment of non-alcoholic fatty liver disease (NAFLD), comprising a Roseburia spp. strain, a Bifidobacterium spp. strain, or extracellular vesicles (EVs)...
|
|
WO/2023/140308A1 |
The present invention addresses the problem of providing a novel composition for the proliferation of Akkemansia muciniphila present in the intestinal flora. The composition for the proliferation of Akkemansia muciniphila contains plat...
|
|
WO/2023/135508A1 |
The present invention relates to pyrrolo[1,2-b]-2-pyridazinone compounds of formula (I), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof as 5-HT4 receptor agonists. The present invention also describe...
|
|
WO/2023/135506A1 |
Provided is (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,
4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Etrasimod, Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof for use in a method of t...
|
|
WO/2023/136312A1 |
The purpose of the present invention is to provide a means for treating liver dysfunction. The problem was solved by providing: a cell culture sheet containing skeletal myoblasts for treating liver dysfunction or for improving liver func...
|
|
WO/2023/135207A1 |
The present invention relates to a pharmaceutical combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, prodrug thereof or a metabolite thereof with a S1P receptor modulator or a pharmaceutically accepta...
|
|
WO/2023/136406A1 |
The objective of the present invention is to provide a composition for the prevention, amelioration, or treatment of bowel diseases caused by fine dust comprising a Eucommia ulmoides leaf fraction as an active ingredient and, more specif...
|
|
WO/2023/137353A1 |
Described herein are 15-PGDH inhibitors and methods of utilizing 15-PGDH inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
|
|
WO/2023/137356A1 |
Described herein are 15-PGDH inhibitors and methods of utilizing 15-PGDH inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
|
|
WO/2023/134725A1 |
A pharmaceutical composition comprising a neurokinin-1 antagonist prodrug compound. A pharmaceutical composition comprising a compound of formula I and a stabilizer, and a preparation method therefor.
|
|
WO/2023/136313A1 |
A purpose of the present invention is to provide a means for treating a hepatic function disorder. The aforementioned problem is solved by, for example: a composition for treating a hepatic function disorder or for ameliorating a hepatic...
|
|
WO/2023/134673A1 |
A high-selectivity KCNQ4 potassium channel agonist of formula I, a preparation method therefor and the use thereof. The compound further improves the KCNQ4 agonistic activity, and is still free of KCNQ2 agonistic activity, thus having ex...
|
|
WO/2023/137178A1 |
Provided is a health supplement product that can be administered to subjects with pre-diabetes and type 2 diabetes, the product comprising a fixed dose combination of vitamin D3, niacinamide (which is a form of vitamin B3), and lipoic ac...
|
|
WO/2023/136329A1 |
The present invention provides: a cell proliferation retardant which contains D-allose and/or a derivative thereof and/or a mixture of D-allose and a derivative thereof as an active ingredient and which prolongs a period retaining in the...
|
|
WO/2023/135505A1 |
The present disclosure relates to methods for treating Sjögren's Syndrome or mixed connective tissue disease using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed herein is a compound of Formula (...
|
|
WO/2023/135274A1 |
The present invention is directed to fermented cereal compositions for treatment of a fatty liver disease or a fibrotic liver disease.
|
|
WO/2023/135595A1 |
The present invention provides compositions and methods for treating gastrointestinal diseases or disorders. In particular, the present invention provides pharmaceutical compositions and formulations comprising psilocybin and an active a...
|
|
WO/2023/134420A1 |
Disclosed are a stachys japonica and dendrobium nobile compound oral liquid, and a preparation method therefor. The stachys/dendrobium oral liquid comprises the following components and mass ratios: 5-20 g of stachys japonica, 2-10 g of ...
|
|
WO/2023/135930A1 |
[Problem] To provide a powder-liquid-type denture base liner that comprises a powder material having a non-crosslinked resin powder and a polymerization initiator as main components, and a liquid material having a radically polymerizable...
|
|
WO/2023/134698A1 |
The present application belongs to the technical field of chemical pharmaceuticals and relates to a compound represented by general formula (I), a racemate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof, a use ...
|
|
WO/2023/134122A1 |
A cell membrane-coated nanodecoy (ND) capable of clearing proinflammatory factors and inhibiting T cell activation, and a preparation method therefor and the use thereof. The nanodecoy comprises: a nano core and a programmed death-ligand...
|
|
WO/2023/131670A2 |
The present invention relates to a composition comprising one or more fructanases and one or more Lactobacillus strains to provide relief from or prevent fructan and/or fructose induced abdominal discomfort; digest fructan and/or fructos...
|
|
WO/2023/132399A1 |
The present invention relates to a composition for the prevention, amelioration or treatment of inflammatory bowel disease, comprising a galacto-oligosaccharide as an active ingredient. The galacto-oligosaccharide composition of the pres...
|
|
WO/2023/133386A1 |
The present disclosure relates to methods and compositions for oral delivery of nutrients and/or pharmaceuticals, particularly for tissue repair and regeneration of the body, and more particularly to methods and compositions for protecti...
|
|
WO/2023/130758A1 |
The present invention provides a sustained-release drug delivery system for oral administration, and a preparation method therefor. According to the present invention, a drug for treating oral diseases is loaded on a porous material, and...
|
|
WO/2023/132609A1 |
The present invention relates to a long-acting fatty acid-peptide derivative and use thereof and, in particular, to a long-acting GLP-1/GLP-2 dual agonist, use thereof for treating intestinal diseases, intestinal damage, or gastric disea...
|
|
WO/2023/130594A1 |
The present invention relates to L-arabinose as well as a preparation and the use thereof. The L-arabinose and the preparation thereof are prepared by means of the following process: (1) dissolving an L-arabinose raw material in water, a...
|
|
WO/2023/131118A1 |
The present disclosure relates to protein degraders developed on the basis of BCL-2 family protein ligand compounds, comprising compounds of formula (I) or salts, enantiomers, stereoisomers, solvates, prodrugs or polymorphs thereof, and ...
|
|
WO/2023/130541A1 |
Provided in the present invention are a 2-pyrazole-3-benzimidazole derivative, a preparation method therefor and the use thereof, the 2-pyrazole-3-benzimidazole derivative having a structure represented by formula (I). Experimental resul...
|
|
WO/2023/131116A1 |
Provided are a carbonyl bridged heterocyclic compound having a structure represented by formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing these compounds, and an applicatio...
|
|
WO/2022/241090A9 |
Provided are methods of treatment comprising administering to a subject, in need thereof, a therapeutically effective amount of activated stem cells to the affected tissue or organ. The methods described herein are treatment modalities e...
|
|
WO/2023/123063A1 |
Provided herein are pharmaceutical compositions comprising therapeutic agent (s) and functional excipients that can enable oral absorption of small molecules and/or large molecules. Also provided herein are methods of preparing the pharm...
|
|
WO/2023/125716A1 |
Provided in the present invention are a class of quinoline compounds and a preparation method therefor, a pharmaceutical composition and the use thereof. Specifically, provided in the present invention are a compound as shown in formula ...
|
|
WO/2023/129215A1 |
The present invention is directed to an aerosol foam composition comprising roflumilast, an emulsifier blend containing cetearyl alcohol, dicetyl phosphate, and ceteareth-10 phosphate and a hydrocarbon propellant. The aerosol foam compos...
|
|
WO/2023/125486A1 |
Provided are a class of compounds which have a structure as shown in the following general formula (I) and are used as somatostatin receptor subtype 5 (SSTR5) antagonists, and a pharmaceutical composition and the use thereof. The compoun...
|
|
WO/2023/124185A1 |
The invention provides an off-the-shelf human umbilical cord derived mesenchymal stem cell, a preparation method thereof, and an application. The preparation method comprises the following steps: culturing an isolated umbilical cord tiss...
|
